Kyntra Bio, Inc. (KYNB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Kyntra Bio, Inc. stock (KYNB) is currently trading at $6.79. Kyntra Bio, Inc. PS ratio (Price-to-Sales) is 4.48. Analyst consensus price target for KYNB is $43.00. WallStSmart rates KYNB as Sell.
- KYNB PE ratio analysis and historical PE chart
- KYNB PS ratio (Price-to-Sales) history and trend
- KYNB intrinsic value — DCF, Graham Number, EPV models
- KYNB stock price prediction 2025 2026 2027 2028 2029 2030
- KYNB fair value vs current price
- KYNB insider transactions and insider buying
- Is KYNB undervalued or overvalued?
- Kyntra Bio, Inc. financial analysis — revenue, earnings, cash flow
- KYNB Piotroski F-Score and Altman Z-Score
- KYNB analyst price target and Smart Rating
Kyntra Bio, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Kyntra Bio, Inc. (KYNB) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in profit margin. Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
Kyntra Bio, Inc. (KYNB) Key Strengths (1)
Keeps $2849 of every $100 in revenue as net profit
Supporting Valuation Data
Kyntra Bio, Inc. (KYNB) Areas to Watch (6)
Losing money on operations
Revenue declining -59.30%, a shrinking business
Very expensive at 80.4x book value
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 4.5x annual revenue
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Kyntra Bio, Inc. (KYNB) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Profit Margin. Profitability is solid with Profit Margin at 2849.00%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Book. Some valuation metrics including Price/Sales (4.48), Price/Book (80.40) suggest expensive pricing. Growth concerns include Revenue Growth at -59.30%, which may limit upside. Profitability pressure is visible in Operating Margin at -1059.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -1059.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -59.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KYNB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KYNB's Price-to-Sales ratio of 4.48x trades 453% above its historical average of 0.81x (99th percentile), historically expensive. The current valuation is 2% below its historical high of 4.59x set in Mar 2026, and 44700% above its historical low of 0.01x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~0.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Kyntra Bio, Inc. (KYNB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Kyntra Bio, Inc. faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 6M with 59% decline year-over-year. Profit margins are strong at 2849.0%, reflecting pricing power and operational efficiency.
Key Findings
Spending 113% of revenue (7M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 59% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -18M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Kyntra Bio, Inc..
Bottom Line
Kyntra Bio, Inc. faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Kyntra Bio, Inc.(KYNB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.